Table 4 Potential drug-cancer associations with numbers of clinical trials
From: A systematic analysis of FDA-approved anticancer drugs
Drug | Possible indication | Number of clinical trialsa | Drug | Possible indication | Number of clinical trialsa |
|---|---|---|---|---|---|
Thalidomide | Lymphoma | 174 | Ziv-aflibercept | Lung cancer | 5 |
Temsirolimus | BRCA | 129 | Afatinib | CRC | 4 |
Cetuximab | Lung cancer | 77 | Axitinib | THC | 4 |
Ofatumumab | Lymphoma | 64 | Gefitinib | PACA | 4 |
Erlotinib | HNC | 62 | Pazopanib | GCA | 4 |
Temsirolimus | PACA | 50 | Pazopanib | CRC | 4 |
Aldesleukin | Lymphoma | 44 | Pertuzumab | GCA | 4 |
Obinutuzumab | Lymphoma | 44 | Regorafenib | KNC | 4 |
Gefitinib | HNC | 43 | Regorafenib | PACA | 4 |
Temsirolimus | BrainC | 40 | Regorafenib | Melanoma | 4 |
Axitinib | KNC | 39 | Tamoxifen citrate | PCa | 4 |
Cetuximab | PACA | 31 | Tositumomab and Iodine I 131 Tositumomab | Leukemia | 4 |
Erlotinib | CRC | 31 | Vandetanib | KNC | 4 |
Panitumumab | HNC | 31 | Vemurafenib | THC | 4 |
Sorafenib | Melanoma | 30 | Ziv-aflibercept | KNC | 4 |
Vandetanib | Lung cancer | 29 | Ado-trastuzumab emtansine | GCA | 3 |
Erlotinib | BRCA | 25 | Afatinib | PACA | 3 |
Sorafenib | PACA | 25 | Bevacizumab | THC | 3 |
Sorafenib | CRC | 23 | Cabozantinib | PACA | 3 |
Trastuzumab | Lung cancer | 22 | Cabozantinib | Sarcoma | 3 |
Vandetanib | HNC | 22 | Dabrafenib | THC | 3 |
Carfilzomib | Lymphoma | 20 | Fulvestrant | PCa | 3 |
Lapatinib | HNC | 20 | Pertuzumab | Lung cancer | 3 |
Afatinib | HNC | 17 | Vandetanib | PACA | 3 |
Sunitinib | Sarcoma | 17 | Ziv-aflibercept | BrainC | 3 |
Panitumumab | Lung cancer | 16 | Axitinib | Sarcoma | 2 |
Sorafenib | Sarcoma | 16 | Axitinib | PACA | 2 |
Sunitinib | Liver cancer | 16 | Axitinib | GCA | 2 |
Cetuximab | BRCA | 14 | Cabozantinib | Liver cancer | 2 |
Peginterferon Alfa-2b | Leukemia | 14 | Denileukin diftitox | KNC | 2 |
Sunitinib | CRC | 14 | Estramustine | BRCA | 2 |
Lapatinib | GCA | 13 | Gefitinib | THC | 2 |
Gefitinib | CRC | 12 | Vandetanib | GCA | 2 |
Gefitinib | BRCA | 12 | Bexarotene | KS | 1 |
Leuprolide | BRCA | 12 | Cabozantinib | CRC | 1 |
Vandetanib | BRCA | 11 | Cabozantinib | GCA | 1 |
Sorafenib | GCA | 10 | Cetuximab | THC | 1 |
Bicalutamide | BRCA | 9 | Crizotinib | THC | 1 |
Denileukin diftitox | Melanoma | 9 | Dabrafenib | KNC | 1 |
Enzalutamide | BRCA | 9 | Dabrafenib | Liver cancer | 1 |
Ibritumomab tiuxetan | Leukemia | 9 | Dabrafenib | CRC | 1 |
Cabozantinib | Lung cancer | 8 | Degarelix | BRCA | 1 |
Regorafenib | Liver cancer | 8 | Erlotinib | THC | 1 |
Lapatinib | Lung cancer | 7 | Lapatinib | THC | 1 |
Lapatinib | CRC | 7 | Peginterferon Alfa-2b | Sarcoma | 1 |
Panitumumab | PACA | 7 | Ramucirumab | PACA | 1 |
Ramucirumab | Liver cancer | 7 | Ramucirumab | Sarcoma | 1 |
Vandetanib | CRC | 7 | Regorafenib | THC | 1 |
Vandetanib | BrainC | 7 | Ziv-aflibercept | THC | 1 |
Ado-trastuzumab emtansine | Lung cancer | 6 | Abarelix | BRCA | 0 |
Axitinib | Liver cancer | 6 | Afatinib | THC | 0 |
Cabozantinib | KNC | 6 | Alitretinoin | Lymphoma | 0 |
Pazopanib | PACA | 6 | Bosutinib | GCA | 0 |
Pazopanib | THC | 6 | Dabrafenib | GCA | 0 |
Ramucirumab | CRC | 6 | Dasatinib | GCA | 0 |
Sunitinib | THC | 6 | Fluoxymesterone | PCa | 0 |
Afatinib | GCA | 5 | Flutamide | BRCA | 0 |
Axitinib | CRC | 5 | Methyltestosterone | PCa | 0 |
Lapatinib | PACA | 5 | Nilotinib | GCA | 0 |
Panitumumab | BRCA | 5 | Nilutamide | BRCA | 0 |
Pazopanib | Liver cancer | 5 | Panitumumab | THC | 0 |
Peginterferon Alfa-2b | Lymphoma | 5 | Ponatinib | GCA | 0 |
Pomalidomide | Lymphoma | 5 | Ramucirumab | THC | 0 |
Ramucirumab | KNC | 5 | Vemurafenib | GCA | 0 |
Regorafenib | Sarcoma | 5 | Vemurafenib | KNC | 0 |
Toremifene | PCa | 5 | Vemurafenib | Liver cancer | 0 |
Vemurafenib | CRC | 5 | Â | Â | Â |